NAD+ precursor
NAD Augmentation for Diabetic Kidney Disease
Recruiting0 awardsPhase 2
Boston, Massachusetts
This trial is testing whether NMN, a compound that may improve cell function, can help older adults with type 2 diabetes and high urine protein levels. The goal is to see if NMN can reduce kidney damage by improving cell energy production. Participants will receive NMN to compare the effects.
Popular Filters
Trials for DKD Patients
SGLT2 Inhibitor
Sotagliflozin for Diabetic Kidney Disease
Recruiting1 awardPhase 3
Stanford, California
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Glucagon-like peptide-1 (GLP-1) receptor agonist
Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
Recruiting0 awardsPhase 2
Aurora, Colorado
"This trial aims to see how semaglutide affects kidney function and oxygen levels in people with type 1 diabetes. It will also look at how semaglutide impacts blood sugar levels and safety
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
Recruiting1 award6 criteria
Milwaukee, Wisconsin
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Biguanide
Metformin + Automated Insulin Delivery for Type 1 Diabetes
Recruiting0 awardsPhase 1
Aurora, Colorado
This trial tests a device that automatically adjusts insulin levels and a medication called metformin in young people with type 1 diabetes. The goal is to see if this combination can better manage blood sugar and improve heart and kidney health. The use of metformin along with insulin therapy has been suggested as a means of improving diabetes control and alleviating weight gain in type 1 diabetes.
Fibrate
Fenofibrate for Type 1 Diabetes
Recruiting0 awardsPhase 2
Boston, Massachusetts
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Trials for Diabetic Nephropathy Patients
SGLT2 Inhibitor
Sotagliflozin for Diabetic Kidney Disease
Recruiting1 awardPhase 3
Stanford, California
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
Recruiting1 award6 criteria
Milwaukee, Wisconsin
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Fibrate
Fenofibrate for Type 1 Diabetes
Recruiting0 awardsPhase 2
Boston, Massachusetts
This trial is to test whether the generic drug fenofibrate can prevent kidney damage in people with type 1 diabetes. 40 participants will be enrolled and given either fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and end of the study.
Mesenchymal Stem Cell Therapy
Stem Cell Therapy for Chronic Kidney Disease
Recruiting1 awardPhase 1
Jacksonville, Florida
This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.
Dietary Supplement
Plant-Focused Diet for Diabetes and Chronic Kidney Disease
Recruiting1 award
Orange, California
"This trial will involve 120 patients with diabetes and kidney disease who will be randomly assigned to follow a plant-focused diet or a standard kidney disease diet for 6 months. The goal is to see if
Trials With No Placebo
SGLT2 Inhibitor
Combo Diabetes Drug for Type 2 Diabetes
Recruiting3 awardsPhase 4
New York, New York
This trial is designed to compare rates of the total number of cardiovascular, kidney, and death events among three alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD.
Behavioural Intervention
Basic Needs Navigation for Diabetic Kidney Disease
Recruiting1 award6 criteria
Milwaukee, Wisconsin
This trial will test a basic needs navigation intervention to see if it can help low-income African Americans with diabetic kidney disease who are experiencing multidimensional adversity. The study will look at feasibility, clinical outcomes, self-care behaviors, and quality of life.
Mesenchymal Stem Cell Therapy
Stem Cell Therapy for Chronic Kidney Disease
Recruiting1 awardPhase 1
Jacksonville, Florida
This trial is testing if using donor stem cells is safe and tolerable for people with chronic kidney disease. The stem cells might help repair their damaged kidneys. Stem cell therapy has shown potential in treating kidney diseases and aiding in kidney regeneration.
Endothelin Receptor Antagonist
Atrasentan for Kidney Disease
Recruiting1 awardPhase 2
Huntsville, Alabama
This trial is testing a pill called atrasentan that may help people with certain kidney diseases by reducing harmful protein levels in their urine. It targets patients whose kidney function is getting worse despite standard treatments. The goal is to see if this medication can protect their kidneys.
Genetic Test for Cardiorenal Complications in Type 2 Diabetes
Recruiting1 award1 criteria
Montreal, Quebec
"This trial aims to see if a genetic risk prediction test can help patients with Type 2 Diabetes avoid heart and kidney complications. Patients will be monitored over 18 months to see if knowing their risk helps
SGLT2 Inhibitor
Canagliflozin for Diabetic Kidney Disease
Recruiting3 awardsPhase 4
Ann Arbor, Michigan
This trial is testing Canagliflozin, a medication that helps remove sugar from the body through urine, on adults with Type 2 diabetes and early kidney disease. The goal is to see if it can protect their kidney function by lowering blood sugar levels.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.